Laura M Periman, Walter O Whitley, Sathi Maiti, James Mun, Anh N Ho, Bhagyashree Oak, Amod Athavale, Elizabeth Yeu
{"title":"美国蠕形螨性眼睑炎的患者旅程和疾病负担。","authors":"Laura M Periman, Walter O Whitley, Sathi Maiti, James Mun, Anh N Ho, Bhagyashree Oak, Amod Athavale, Elizabeth Yeu","doi":"10.1080/13696998.2025.2500224","DOIUrl":null,"url":null,"abstract":"<p><strong>Aim: </strong><i>Demodex</i> blepharitis (DB) is a chronic eyelid disease caused by an infestation of <i>Demodex</i> mites. The objective of this chart audit study was to characterize the patient journey and burden of illness associated with DB from an eye-care provider's perspective.</p><p><strong>Methods: </strong>Retrospective medical data for patients with a confirmed diagnosis of DB were anonymously collected <i>via</i> ophthalmologists and optometrists in the US (collectively eye-care providers [ECPs]), in June-July 2022. Each eligible ECP completed a questionnaire and provided chart abstractions of 1-5 medical charts of patients with DB in an electronic case report form.</p><p><strong>Results: </strong>All ECPs (<i>N</i> = 61) were ophthalmologists or optometrists who worked primarily in office-based private practices (97%). Data from 192 medical charts of patients with an ECP-confirmed diagnosis of DB were abstracted and their demographics included 54% males and 71% Caucasians. The mean time (±SD) since diagnosis was 11 (±9.0) years. Over 40% of patients were not examined for DB at initial presentation, and the average time from initial presentation to a definitive diagnosis for DB was 6.5 months. After DB diagnosis and across the period of observation until the time of the study, patients had a mean (±SD) of 3.2 (±2.8) follow-up visits due to DB and continued to use multiple off-label prescription and over-the-counter therapies for symptom management.</p><p><strong>Limitation: </strong>Medical records may be incomplete or inconsistently reported and subject to recall bias.</p><p><strong>Conclusions: </strong>The patient journey is lengthy with multiple challenges, including delay in DB diagnosis and recurring DB symptoms, underlining an urgent need for action to improve diagnosis and treatment of DB.</p>","PeriodicalId":16229,"journal":{"name":"Journal of Medical Economics","volume":" ","pages":"734-742"},"PeriodicalIF":2.9000,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The patient journey and burden of disease in <i>Demodex</i> blepharitis in the United States.\",\"authors\":\"Laura M Periman, Walter O Whitley, Sathi Maiti, James Mun, Anh N Ho, Bhagyashree Oak, Amod Athavale, Elizabeth Yeu\",\"doi\":\"10.1080/13696998.2025.2500224\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Aim: </strong><i>Demodex</i> blepharitis (DB) is a chronic eyelid disease caused by an infestation of <i>Demodex</i> mites. The objective of this chart audit study was to characterize the patient journey and burden of illness associated with DB from an eye-care provider's perspective.</p><p><strong>Methods: </strong>Retrospective medical data for patients with a confirmed diagnosis of DB were anonymously collected <i>via</i> ophthalmologists and optometrists in the US (collectively eye-care providers [ECPs]), in June-July 2022. Each eligible ECP completed a questionnaire and provided chart abstractions of 1-5 medical charts of patients with DB in an electronic case report form.</p><p><strong>Results: </strong>All ECPs (<i>N</i> = 61) were ophthalmologists or optometrists who worked primarily in office-based private practices (97%). Data from 192 medical charts of patients with an ECP-confirmed diagnosis of DB were abstracted and their demographics included 54% males and 71% Caucasians. The mean time (±SD) since diagnosis was 11 (±9.0) years. Over 40% of patients were not examined for DB at initial presentation, and the average time from initial presentation to a definitive diagnosis for DB was 6.5 months. After DB diagnosis and across the period of observation until the time of the study, patients had a mean (±SD) of 3.2 (±2.8) follow-up visits due to DB and continued to use multiple off-label prescription and over-the-counter therapies for symptom management.</p><p><strong>Limitation: </strong>Medical records may be incomplete or inconsistently reported and subject to recall bias.</p><p><strong>Conclusions: </strong>The patient journey is lengthy with multiple challenges, including delay in DB diagnosis and recurring DB symptoms, underlining an urgent need for action to improve diagnosis and treatment of DB.</p>\",\"PeriodicalId\":16229,\"journal\":{\"name\":\"Journal of Medical Economics\",\"volume\":\" \",\"pages\":\"734-742\"},\"PeriodicalIF\":2.9000,\"publicationDate\":\"2025-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Medical Economics\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/13696998.2025.2500224\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/5/21 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"HEALTH CARE SCIENCES & SERVICES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Medical Economics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/13696998.2025.2500224","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/5/21 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}
The patient journey and burden of disease in Demodex blepharitis in the United States.
Aim: Demodex blepharitis (DB) is a chronic eyelid disease caused by an infestation of Demodex mites. The objective of this chart audit study was to characterize the patient journey and burden of illness associated with DB from an eye-care provider's perspective.
Methods: Retrospective medical data for patients with a confirmed diagnosis of DB were anonymously collected via ophthalmologists and optometrists in the US (collectively eye-care providers [ECPs]), in June-July 2022. Each eligible ECP completed a questionnaire and provided chart abstractions of 1-5 medical charts of patients with DB in an electronic case report form.
Results: All ECPs (N = 61) were ophthalmologists or optometrists who worked primarily in office-based private practices (97%). Data from 192 medical charts of patients with an ECP-confirmed diagnosis of DB were abstracted and their demographics included 54% males and 71% Caucasians. The mean time (±SD) since diagnosis was 11 (±9.0) years. Over 40% of patients were not examined for DB at initial presentation, and the average time from initial presentation to a definitive diagnosis for DB was 6.5 months. After DB diagnosis and across the period of observation until the time of the study, patients had a mean (±SD) of 3.2 (±2.8) follow-up visits due to DB and continued to use multiple off-label prescription and over-the-counter therapies for symptom management.
Limitation: Medical records may be incomplete or inconsistently reported and subject to recall bias.
Conclusions: The patient journey is lengthy with multiple challenges, including delay in DB diagnosis and recurring DB symptoms, underlining an urgent need for action to improve diagnosis and treatment of DB.
期刊介绍:
Journal of Medical Economics'' mission is to provide ethical, unbiased and rapid publication of quality content that is validated by rigorous peer review. The aim of Journal of Medical Economics is to serve the information needs of the pharmacoeconomics and healthcare research community, to help translate research advances into patient care and be a leader in transparency/disclosure by facilitating a collaborative and honest approach to publication.
Journal of Medical Economics publishes high-quality economic assessments of novel therapeutic and device interventions for an international audience